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Alkylanilines are a group of chemicals whose ubiquitous pres-
ence in the environment is a result of the multitude of sources
from which they originate. Exposure assessments indicate that
most individuals experience lifelong exposure to these com-
pounds. Many alkylanilines have biological activity similar to
that of the carcinogenic multi-ring aromatic amines. This review
provides an overview of human exposure and biological effects.
It also describes recent investigations into the biochemical mech-
anisms of action that lead to the assessment that they are most
probably more complex than those of the more extensively in-
vestigated multi-ring aromatic amines. Not only is nitrenium ion
chemistry implicated in DNA damage by alkylanilines but also
reactions involving quinone imines and perhaps reactive oxygen
species. Recent results described here indicate that alkylanilines
can be potent genotoxins for cultured mammalian cells when
activated by exogenous or endogenous phase I and phase II
xenobiotic-metabolizing enzymes. The nature of specific DNA
damage products responsible for mutagenicity remains to be
identified but evidence to date supports mechanisms of activa-
tion through obligatory N-hydroxylation as well as subsequent
conjugation by sulfation and/or acetylation. A fuller under-
standing of the mechanisms of alkylaniline genotoxicity is
expected to provide important insights into the environmental
and genetic origins of one or more human cancers and may
reveal a substantial role for this group of compounds as potential
human chemical carcinogens.
Introduction
Aromatic amines are a class of organic compounds that include many
members that are carcinogenic, both experimentally in the research
setting and experientially in human life. The carcinogenesis literature
documents innumerable studies demonstrating that administration of
a considerable variety of aromatic amines to experimental animals of
different species induces cancers in those animals (1). The epidemi-
ological literature leaves little doubt that a specific few aromatic
amines are the cause of bladder cancer in occupationally exposed
persons and there is a convincing argument to be made that exposure
to aromatic amines via tobacco smoke is a major, if not predominant,
factor in causing bladder cancer in smokers (2).
The biochemical mechanisms by which aromatic amines might
induce cancers have been investigated extensively and are now
thought to be reasonably well understood (3–5). Human population
studies that have incorporated measures of metabolic genotype and
phenotype tend to support the biochemical mechanisms inferred from
experimental studies (6). It appears that, for this class of chemical
carcinogens, the linkage between the experimental setting and the
human condition is as strong as any. Yet, there remains a conundrum:
outside the occupational setting there appears to be far too little
exposure to any of the known human bladder carcinogens to account
for the observed incidence rates.
Various possibilities may be considered for resolving this conun-
drum. The models used for extrapolating from high to low dose may
underestimate potency at human exposure levels. There may be envi-
ronmental exposures to known compounds that are largely cryptic or
there may be amines in the environment that have not yet been iden-
tified. Unanticipated synergies among multiple exposures may occur.
Other possibilities no doubts exist. Because of their environmental
prevalence, one relatively unexplored group of aromatic amines, the
alkylanilines, may be significantly involved in one or more of these
explanations. In this paper, we will review much of the research on
alkylanilines that addresses the question of why they could be playing
an important role in human cancer.
Environmental prevalence
In considering the importance of any specific chemical carcinogen
or class of carcinogens to human disease incidence, weight must be
given to the extent to which the compounds are distributed in the
environment. Alkylanilines, as a class, appear to be distributed
widely, making exposure to them nearly ubiquitous. Early efforts
at exposure assessment were predicated on the fact that alkylanilines
are present in tobacco smoke (7–9). Accordingly, indoor spaces
contaminated with tobacco smoke exhibited higher levels of alkyla-
nilines than uncontaminated spaces (8,10). Outdoor air was gener-
ally lower with exceptions that may be attributable to industrial
sources (10). Exposure assessment based on hemoglobin adduct
levels also indicates that tobacco smoke is a significant, if not pre-
dominant, source for many alkylanilines (11,12). In both studies,
2,6-dimethylaniline (2,6-DMA) was an exception, being actually
higher in non-smokers than smokers in a study conducted in Italy
(11). Much higher levels (7- to 8-fold) of 3,5-dimethylaniline (3,5-
DMA) were also observed in non-smokers in the Italian population.
This finding attains greater significance in light of a recent investi-
gation in Canada (13) that found levels of 3,5-DMA in indoor and
outdoor air that are two to three orders of magnitude higher than
those reported elsewhere.
Exposure assessment through hemoglobin adduct analysis has
now been extended to include non-tobacco sources in the USA
(12), Italy (11), Germany (14) and most recently by us in China
(unpublished results). In all of these studies, there have been virtu-
ally no subjects that do not have hemoglobin adducts of all of the
compounds investigated. Results tend to be comparable: while there
may be a considerable range of values among individual subjects,
mean values tend to fall within a range of,10-fold. The inescapable
conclusion from these results is that environmental prevalence of
many alkylanilines is extensive and that exposure to them is not
confined to limited population subgroups such as the occupationally
exposed.
Figure 1 illustrates most of the important routes by which alkylani-
lines come to be present in the environment. It is based on the com-
prehensive information about production and possible releases into
the environment of specific alkylanilines that can be found in the
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Evidence for carcinogenicity in a population-based study
In 2004, we published results from a population-based study of blad-
der cancer conducted in Los Angeles county in which chemical
markers of exposure to a specific set of alkylanilines were included
(12). This was the first, and is still the only, population-based bladder
cancer study of any aromatic amines having the basic aniline ring
structure. In the absence of additional studies with similar findings,
the results are not definitive, but considering the power of the
study, we were strongly motivated to pursue additional mechanistic
and in vitro toxicology studies in an effort to provide biological
plausibility for the epidemiological findings.
The Los Angeles study examined exposure to nine different alky-
lanilines, including all three ethyl and all six dimethyl isomers. Sta-
tistical analysis found that three of the nine—2,6-DMA, 3,5-DMA
and 3-ethylaniline (3-EA)—were independently associated with risk
for development of bladder cancer. Others were also associated with
risk but not independently as there were strong correlations among the
various anilines as well as with 4-aminobiphenyl exposure. Impor-
tantly, no meaningful differences were found when analysis was re-
stricted to lifelong non-smokers, implying that smoking was not
a confounder in this study.
Evidence for carcinogenicity from occupational exposure
There exist only very limited data from occupational studies that bear
directly on the human carcinogenicity of monocyclic amines and none
specifically related to the alkylanilines discussed here. The closest
analog that has been evaluated comprehensively is o-toluidine. In
a study of workers exposed to aniline and o-toluidine, it was found
that levels of exposure to these chemicals were associated with a sta-
tistically significant increase in incidence of bladder cancer (15). The
initial report did not distinguish between aniline and o-toluidine ex-
posure but argued that the latter was more important. The study was
challenged (16,17) on the grounds that prior exposure of the same
workers to more potent chemicals could not be ruled out or could
ongoing exposure to 4-aminobiphenyl (4-ABP). The issue of prior
exposure was rebutted (18,19) and the issue of ongoing 4-ABP expo-
sure was addressed through a follow-up study in which current expo-
sure to aniline, o-toluidine and 4-ABP was assessed through
biomonitoring of hemoglobin adducts (20). Biomonitoring clearly
revealed that 4-ABP exposure was independent of workplace expo-
sure status and, as observed in numerous other studies, was mostly
associated with cigarette consumption. Thus, the most probable find-
ing of this retrospective cohort study is that o-toluidine is indeed
a human bladder carcinogen. A follow-up study at the same chemical
plant reported in 2004 (21), long after potential co-exposures to other
chemicals is thought to have ceased, revealed a continuing excess of
bladder cancer among exposed workers.
Experimental carcinogenicity
A comprehensive review of the carcinogenicity of alkylanilines is
outside the scope of this paper mainly because so many of the results,
while suggestive of carcinogenic potential, are largely inconclusive.
Furthermore, the National Toxicology Program has recently con-
ducted a review of the literature as part of its process for nominating
several alkylanilines for future study. The review can be found in the
nominating document at http://ntp.niehs.nih.gov/ntp/noms/Support_
Docs/Alkylanilines060809.pdf. The document includes genotoxicity
data as well and therefore covers an expanded set of 14 compounds.
Here, we will focus on the two compounds for which the International
Agency for Cancer has found sufficient evidence to categorize them as
either carcinogenic to humans (o-toluidine; Group 1) or possibly car-
cinogenic to humans (2,6-DMA; Group 2B).
As described by the International Agency for Cancer, ‘ortho-tolu-
idine was tested for carcinogenicity as its hydrochloride salt in two
experiments in mice and in three experiments in rats and as the free
base in one limited experiment in hamsters. After oral administration
to mice, it induced an increased incidence of haemangiomas and
haemangiosarcomas and hepatocellular carcinomas or adenomas. In
rats, oral administration of ortho-toluidine increased the incidence of
tumours in multiple organs, including fibromas, sarcomas, mesothe-
liomas, mammary fibroadenomas and transitional cell carcinomas of
the urinary bladder’. Based on these results, the International Agency
for Cancer has concluded that there is sufficient evidence for the
carcinogenicity of o-toluidine in experimental animals. The lack
of organ specificity casts some doubt on the significance of this con-
clusion but the occurrence of transitional cell carcinomas of the uri-
nary bladder is notable, as this is typical of many aromatic amine
carcinogens.
In contrast to o-toluidine, 2,6-DMA is an organ-specific
carcinogen, inducing carcinomas and papillary adenomas of the nasal
cavity in male and female rats in a dose-dependent manner (22).
Subsequent studies strengthen the bioassay findings. When [14C]-
2,6-DMA was given to rats, DNA in the ethmoid turbinate as well
as in liver became radiolabeled (23). In contrast to hepatic DNA,
labeling of the ethmoid turbinate DNA was only observable after
pretreatment with unlabeled 2,6-DMA, indicating that the amine in-
duced an enzyme present in the nasal cavity that is responsible for its
activation and that the same enzyme is a minor constituent in liver.
Recent studies in our laboratories support this inference: when various
sources of P450s were screened for their ability to convert 2,6-DMA
to the corresponding hydroxylamine, rat liver microsomes exhibited
undetectable activity, whereas human liver microsomal activity was
readily apparent (24; unpublished results). Of five recombinant hu-
man P450s tested (1A1, 1A2, 1B1, 2A6 and 2E1), only 2A6 exhibited
N-hydroxylation activity. Notably, one member of the 2A family,
2A3, appears to be expressed preferentially in the rat nasal cavity (25).
Chemical reactivity: comparison of alkylanilines with multi-ring
carcinogenic amines
A paradigmatic model for aromatic amine genotoxicity has evolved
over the last forty years from the seminal work of James and Elizabeth
Miller and their coworkers that is described in detail in several later
publications (5,26,27). In this model, aromatic amines (and amides)
first undergo P450-catalyzed oxidation at the nitrogen atom. The
resulting N-hydroxylamine has the potential to undergo N–O bond
heterolysis to produce a reactive nitrenium ion that reacts with nucle-
obases in DNA to induce genotoxicity. Heterolysis is promoted in
most cases by the intermediate step of phase II conjugation of the
hydroxyl group but may also be catalyzed by protonation.
In view of the apparent genotoxicity or carcinogenicity of at least
some aniline derivatives, several groups have undertaken investigations
to determine whether the nitrenium ion mechanism of DNA damage
HN 2
R1 R, 2 R…, n
occabot
ekoms
evitiguf
snoissime
stnaroloc
sgurdrotom sleuf
sedicitsep
Fig. 1. Environmental sources of alkylanilines.
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is operative for single-ring aromatic amines. Certainly, DNA adducts
of the same basic structure as formed by multi-ring amines can be
synthesized via nitrenium ions. Aniline, the simplest aromatic amine,
forms the dG–C8 adduct when it is present in the reaction in the
activated form, N-acetoxyaniline (28). Marques et al. first reported
the synthesis of dG–C8 adducts of o-, m- and p-toluidine, 2,3-
dimethylaniline and 2,4-dimethylaniline by reaction of the correspond-
ing N-(acyloxy)arylamines with dG, dG nucleotides and DNA, where
the acyl group was either acetyl or pivaloyl (29). They later reported dG
adducts of all the isomeric methyl, ethyl and dimethylanilines using the
same synthetic methods (30). dG adducts of p-chloroaniline and p-ani-
sidine have also been described as products of synthesis via nitrenium
ion chemistry (31). Jones et al. (32) later expanded the range of
substituted anilines that form dG adducts through their acyloxy deriv-
atives to include 2-chloroaniline. The structures of these and the other
adducts described below are shown in Figure 2.
A more detailed study of 2,6-DMA revealed that not only does this
aniline form C8 adducts with dG but also its acyloxy derivative reacts
with DNA to form two other dG adducts (33). One occurs by forming
a bond between the para-carbon and O6 of the nucleobase, whereas
the other occurs by attack at N2. One dA adduct is also formed, again
by attack of the para-carbon, in this case at N6 of the nucleobase. In
our own work, we found that 3,5-DMA, when converted to the ace-
toxy derivative, produces four distinct adducts in DNA (34). One was
the expected dG adduct. The analagous dA–C8 adduct also occurred.
In addition, there was the adduct formed by attack of the para-carbon
at N6 of adenine, as was reported for 2,6-DMA. Lastly, we found an
adduct formed with dC through attack of the nitrogen atom at C5 of
the nucleobase. Despite the novelty of two of the adducts, all were
consistent with the intermediacy of a nitrenium ion.
Demonstration that the DNA adducts expected from nitrenium ion
chemistry do occur when DNA is treated with appropriately activated
alkylanilines may be considered a necessary condition to expect their
occurrence in vivo following exposure to the parent amines. Following
up on these demonstrations, several attempts have been made to detect
the chemically synthesized adducts in treated animals. Jones et al.
(32) developed a method for quantitative analysis of dG and dA
adducts of a set of aromatic amines that included the three toluidines,
2,4-dimethylaniline and 2,6-DMA. The method was based on HPLC/
MS/MS and could distinguish among different adduct structures.
When hepatic DNA from rats given 0.5 mmol/kg of the compounds
was analyzed, no adducts of any of the monocyclic amines were
detected above the level of 3.2 adducts per 108 normal bases. A poly-
cyclic aromatic amine, 4-aminobiphenyl, was included for compari-
son and it produced adducts at 500 per 108 bases.
Adopting a different strategy (35), we treated wild-type C57/BL6
mice with [14C]-labeled 2,6-DMA, 3,5-DMA and 3-EA and analyzed
tissue DNA for isotopic labeling by accelerator mass spectrometry.
All the compounds produced detectable labeling of DNA at levels that
ranged up to more than one per 107 bases for 3,5-DMA in liver. In this
experiment, the dose of alkylaniline was 1 lmol/kg, which is
1/500th of the dose given in the experiment described above where
no adducts were detectable. Only one alkylaniline, 2,6-DMA, is com-
mon to both studies. In our study, it also produced adducts at the level
of one per 107 bases but only at 4 h post-dosing; at 24 h—the time
point used in the other study—the level had declined to about one per
108 bases. While this level is below the limit of detection by the
HPLC/MS/MS method, the difference in dose should be kept in mind
when comparing the two studies.
Since the analytical method we used, accelerator mass spectrom-
etry, was capable only of detecting isotope, it cannot be inferred that
any of the adducts detected were structurally identical with any of
the adducts produced by nitrenium ion reactions. To gain further
insight into the nature of the bound isotope, we have been perform-
ing high-performance liquid chromatography analyses of enzymatic
digests of the DNA isolated from tissues harvested from animals
given [14C]-labeled 3,5-DMA. The choice of 3,5-DMA-treated ani-
mals was governed by the availability of nitrenium adducts of
Fig. 2. Structures of the various alkylaniline DNA adducts that have been elucidated.
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defined structure as described above (34). Digests of hepatic DNA
were combined with a mixture of the four adduct standards at a level
that produced well-defined UV-detectable peaks in the chromato-
gram and subjected to high-performance liquid chromatography
analysis with fraction collection. Accelerator mass spectrometry
analysis of the collected fractions was performed to generate
a radiochromatogram that could be compared with the UV trace.
Several such analyses have been conducted with inconsistent results
in the radiochromatograms. In none of the analyses, though, have we
observed co-chromatography of radiocarbon with UV peaks pro-
duced by the standards, suggesting that if any of the DNA adducts
formed in vivo are identical to the standards they are present only as
minor constituents.
Thus, far, little evidence has been developed to support a model for
genotoxicity of alkylanilines that is comparable with the very success-
ful model that characterizes multicyclic aromatic amine carcinoge-
nicity. However, the available information is far from sufficient to rule
the model out and the ability of nitrenium ions derived from mono-
cyclic amines to form DNA adducts is reason to remain open minded.
In the next section, then, we will show that N-hydroxylation, a critical
metabolic step for activating many aromatic amines, is important also
in monocyclic amine genotoxicity.
N-hydroxylation as a critical activation step
There is ample evidence that alkylanilines and other monocyclic amines
are readily N-hydroxylated by mammalian metabolism. In perhaps, the
most extensive investigation of the phenomenon to date, Sabbioni (36)
tested 32 compounds in rats for their ability to bind to hemoglobin in
a manner that is demonstrative of the generation of N-hydroxylamines
in vivo. Only one of the 32 appeared to be resistant to metabolic trans-
formation to a hemoglobin-binding hydroxylamine. Data from human
studies are similarly indicative that alkylanilines are near-universally
susceptible to metabolic N-hydroxylation (11). Direct evidence for
production of an N-hydroxylamine in vivo in rats has also been pre-
sented by Kulkarni et al. (37), who demonstrated urinary excretion of
N-hydroxy-o-toluidine following administration of the amine.
It has thus widely been assumed that generation of N-hydroxyl-
amines in vivo is associated with genotoxicity but never demonstrated
that N-hydroxylation is a critical step in leading to DNA adduct
formation or damage. We recently undertook a multi-species multi-
compound study to assess the role of N-hydroxylation (38). Using S9
from human, rat, dog and mouse liver, we determined the dependence
of DNA adduct formation by three alkylanilines in vitro on the pres-
ence of NADPH. Results and experimental details are given in Table I.
It is clear from the data that NADPH is a nearly absolute requirement
for DNA adduct formation to occur. Whether the levels observed in
the absence of NADPH represent true adduct formation is difficult to
assess. Control experiments were conducted in which [14C]alkylani-
lines were not added until immediately before terminating the incu-
bation in order to assess non-covalent binding. Results from those
experiments were comparable with results from experiments in which
NADPH was omitted; thus, it is not apparent that any adduct forma-
tion occurred in the absence of NADPH.
Not all the ramifications implicit in the data given in Table I
have been explored in detail but one feature in particular deserves
further discussion. Little activation of 3-EA to DNA-binding me-
tabolites was observed using S9 from three of the four species,
mouse being the exception. This finding was discordant with results
for N-hydroxylation, which indicated that 3-EA was generally
N-hydroxylated at a rate several times greater than the rates ob-
served with 3,5-DMA or 2,6-DMA (38). To explore this discrepancy
further, DNA binding was measured at lower concentrations of al-
kylanilines using human S9. At 25–1000 nM, the same order of
reactivity was observed as at 25 lM but the differences between
3-EA and the other two alkylanilines were much smaller, ranging
from nearly identical to 6-fold less (Figure 3). N-hydroxylation
rates at the lower substrate concentrations have not been measured;
so we can only speculate about the reasons for the change in relative
DNA adduct formation. One possibility is that generation of the
ultimate electrophilic species from 3-EA, whether directly from
the N-hydroxylamine or by a different pathway, becomes kinetically
favored at lower substrate concentration. Whatever the actual
explanation, the results are equivocal with regard to the role of
N-hydroxylamines in DNA adduct formation.
Further studies to attempt to demonstrate involvement of
N-hydroxylamine derivatives in DNA damage involved manipulating
in vitro activation systems with respect to phase II metabolism. Using
the same three alkylanilines listed in Table I, we assessed DNA bind-
ing of radioisotope catalyzed by human liver S9 in the absence and
presence of cofactors that promote N-acetyltransferase (NAT), sulfo-
transferase and glucuronyl transferase activities. Results are presented
in Figure 4, along with experimental details.
Promotion of NAT activity did not have the same effect on all the
compounds tested. It produced a striking negative effect on binding by
2,6-DMA, decreasing the adduct level by 78%. The effect on 3-EA
binding was also negative but considerably smaller at 28%. In con-
trast, the effect with 3,5-DMA was to enhance adduct formation by
53%. Decreased binding under the conditions of the experiment is
uninformative with respect to role of an N-hydroxylamine in DNA
adduct formation because the non-oxidized amine is frequently
a substrate for NAT. Enhancement, though, is a better indicator
because O-acetylation of the hydroxylamine promotes its reactivity.
Results appear to indicate a significant role for the N-hydroxylamine
Table I. Formation of DNA adducts by three [14C]alkylanilinesa
3-EA 3,5-DMA 2,6-DMA
Human Control 15 ± 6 36 ± 11 13 ± 1
Experiment 15 ± 3 1392 ± 74 258 ± 187
Rat Control 39 ± 12 5 ± 1 11 ± 1
Experiment 30 ± 5 1101 ± 204 50 ± 39
Dog Control 15 ± 8 21 ± 14 35 ± 21
Experiment 22 ± 1 727 ± 37 180 ± 53
Mouse Control 68 ± 16 77 ± 23 33 ± 2
Experiment 162 ± 9 139 ± 35 146 ± 22
aValues are given as number of adducts per 108 normal nucleotides (±SD;
N 5 4) and were determined by accelerator mass spectrometry analysis of the
amount of radioisotope bound to DNA after purification. Calf thymus DNA
was incubated in vitro with 25 lM of each alkylaniline and hepatic S9 from
each of four species with and without NADPH. Each 0.2 ml incubation also
included 1 mg/ml DNA, 2 mg/ml S9, 50 mM pH 7.4 Tris buffer and an
NADPH-regenerating system (1.3 mM NADPþ, 3.3 mM glucose-6-
phosphate, 3.3 mM MgCl2 and 0.1 U glucose-6-phosphate dehydrogenase).
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Fig. 3. Formation of DNA adducts catalyzed by human S9 at low doses.
Experimental details given in footnote to Table I except that the alkylaniline
concentrations used were 25, 100 and 1000 nM.
Alkylanilines as potential human carcinogens
53
of 3,5-DMA in DNA binding (but, see comments on Bamberger
rearrangement below).
Likewise, the promotion of DNA binding of all three alkylanilines
by sulfotransferase activity points to a significant role for
N-hydroxylation since it would be expected to produce sulfate esters,
which, like acyl esters, are more reactive than the unconjugated hy-
droxylamines. Decreased binding as a result of promotion of glucur-
onyl transferase activity is largely uninformative, again because the
non-oxidized amine can be a substrate.
Other mechanisms—N-hydroxylation as a first step to other
genotoxins
Largely overlooked until recently is the potential existence of other
chemical reaction pathways leading to DNA adducts or other DNA
damage that do not directly involve electrophilic nitrenium ions.
Phenols are prominent products of aromatic amine metabolism that
may arise by direct oxidation of the aromatic ring or, as others have
conjectured on theoretical grounds (39), from the radical cation that is
the precursor to the N-hydroxylamine as shown in Figure 5. The
phenols have generally been regarded as detoxification products. To
the extent that the phenols are subsequently conjugated with sulfate,
this is probably accurate because sulfates are highly polar water-
soluble compounds. Moreover, with the acidic proton of the phenol
no longer present, the aminophenol is highly resistant to oxidation. If
the phenolic oxygen is not conjugated, the aminophenol can undergo
spontaneous or peroxidase-catalyzed oxidation, as shown in Figure 5,
to a quinone imine, which is highly reactive as an electrophile and can
undergo redox cycling as well.
Significantly, complicating any analysis of the role played by ami-
nophenol products of metabolism is the fact that these compounds can
also form by rearrangement of existing N-hydroxylamines. As a chem-
ical reaction, this transformation is referred to as the Bamberger re-
arrangement and requires strong acid catalysis. It also proceeds in
biological systems, where the rearrangement can be catalyzed by
cytochrome P450 2E1, alcohol dehydrogenase and perhaps other
enzymes as discussed or referenced in ref. (40). Thus, whenever an
N-hydroxylamine is introduced into a biological system, the possibil-
ity that it is converted into an aminophenol before it undergoes any
direct reaction with a biological target must be considered.
Direct evidence of genotoxicity of quinone imines has been re-
ported (41) from studies that measured sister chromatid exchanges
in cultured human lymphocytes. Of particular note is that Hill et al.
included the p-quinone imine derived from 2,6-DMA in the study and
found that it induced sister chromatid exchanges at doses as low as
0.1 lM. Most of the evidence, though, for biological activity of quinone
imines or aminophenols comes from studies of other toxic effects.
Circumstantial evidence for a possible role of quinone imines in
alkylaniline cytotoxicity comes from studies of acetaminophen link-
ing the transcription factors Nrf2 and Keap1 and toxicity. Oxidation of
acetaminophen to N-acetyl-p-benzoquinone imine is thought to be
largely responsible for the hepatoxicity of this widely used analgesic.
Nrf2-null mutant mice consequently exhibit increased sensitivity to
acetaminophen hepatoxicity (42,43). More recently, it has also been
demonstrated that Keap1-knockout mice acquire resistance against
acetaminophen hepatoxicity through activation of Nrf2-antioxidant-
responsive element pathways (44). Similarly, it has also been shown
that acetaminophen can initiate nuclear translocation of Nrf2 in vivo
in mice (45) and that it is then functionally active.
Aminophenols are better known as nephrotoxins than genotoxins
but their mechanistic actions may be similar in that they are electro-
philic reactants. The chemical reaction pathways shown in Figure 6
are presented as an illustration of current hypotheses to explain the
nephrotoxicity and nephrocarcinogenicity of aminophenol/quinone
imines as well as the closely related hydroquinone/quinones. At pres-
ent, available data support a mechanism in which oxidation and
glutathione conjugation occur in the liver. Mono-, bis- and tris-
glutathionyl adducts are exported and taken up by the kidney where
conversion to mercapturic acids occurs to a variable extent. Lastly, the
thioether conjugates become bound to proteins through the same
Michael reaction that produces the glutathione adducts or through
addition–elimination reactions in which the protein displaces one of
the thioether moieties. Examples of each of these steps have been
reported (46–48), including the formation of multiple glutathione
adducts of aminophenol (49) as well as the aminophenol metabolite
of 3-(N-phenylamino)propane-1,2-diol considered responsible for
toxic oil syndrome (50). Further studies (51,52) have probed the mo-
lecular biological effects of 2,3,5-tris-(glutathion-S-yl)hydroquinone
(TGHQ) as well as effects on cell signaling and mutagenesis (53–55).
Other important findings discussed in Shao et al. (56) indicate that
p-aminophenol nephrotoxicity in vivo is mediated by extrarenal bio-
activation comprised of both oxidation and glutathione conjugation. A
full mechanistic understanding of the toxicity of aminophenols has
not yet been developed, but the evidence at this stage points to a cen-
tral role for quinone imines. Whether they also can react directly with
DNA to produce genotoxic outcomes remains an open question.
Studies on the effects of TGHQ on cell signaling are of additional
interest because they suggest yet another mechanism through which
these species may be capable of producing toxic responses: generation
of reactive oxygen species (ROS). TGHQ was reported to induce
mutation spectra in the supF gene replicated in human AD293 cells
and bacterial MBL50 cells that were similar to those induced by
hydroxyl radical (53), one of several ROS. TGHQ reportedly modu-
lates 12-O-tetradecanoyl phorbol 13-acetate responsive element and
nuclear factor-kappaB-binding activity in an ROS-dependent fashion
(54) and exhibits other ROS-inducible events such as posttranslational
modification of Bcl-2 and subcellular localization of Bax, culminating
in the release of cytochrome c and caspase activation (55). Whether
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Fig. 5. Generation of aminophenols/quinone imines from N-hydroxylamines.
The transformations shown here are alternative routes to aminophenols
produced by direct ring oxidation by P450s.
Fig. 4. Effect of Phase II conjugation activity on DNA adduct formation
in vitro. NAT: All incubations were conducted in 0.2 ml 50 mM Tris buffer (pH
7.4) containing 1 mg/ml ct-DNA, 2 mg/ml human liver S9 fraction, NADPH-
regenerating system and 1 lM of the respective [14C]amine for 6 h at 37C.
Supplementation was as follows: NAT, 1 mM ethylenediaminetetraacetic acid,
1 mM dithiothreitol, 1.08 mg/ml acetyl-D,L-carnitine, 0.22 U/ml carnitine
acetyltransferase and 0.1 mM acetyl coenzyme A; SULF, 0.1 mM PAPS and
UGT, 8 mM MgCl2, 25 lg/ml alamethicin and 2 mM UDPGA.
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similar effects could be elicited by glutathione conjugates of quinone
imines remain unexplored but considering the very close similarity
between quinone imines and quinones it seems probably that gener-
ation of ROS by the former occurs in vivo.
Evidence of alkylaniline genotoxicity: recent in vitro studies in
mammalian cells
Genotoxicity of alkylanilines has received very limited investigation
to date, and the fragmented available database supports only limited
conclusions. Combined evidence produced in cultured hepatocytes
and cell-free systems, some of which has been discussed above,
show that both phase 1 (N-hydroxylation) and phase 2 metabolism
(mainly sulfation or acetylation) are required for activation of the
alkylanilines to DNA-binding forms. Proposed metabolic pathways
leading to the formation of genotoxic DNA damage products of
2,6-DMA are summarized in Figure 7. The proposed pathways
provide the rationale underlying our experimental approaches to
characterize mechanisms of mutagenesis and cytotoxicity of this
class of chemicals.
Most previous investigations have focused on 2,6-DMA, in view of
its demonstrable carcinogenic activity for the nasal cavity of rats.
Information published to date can be briefly summarized as follows.
In the Salmonella typhimurium assay, 2,3-, 2,4-, 2,5- and 3,4-
dimethylanilines were weakly mutagenic and caused DNA damage
in mammalian V79 cells (57). In the same assay procedure, 2,6-DMA
was neither mutagenic in multiple bacterial strains in the presence or
absence of exogenous activating systems nor was it active in a DNA
damage and repair assay in Escherichia coli. It induced mutations in
mouse L5178Y lymphoma cells and sister chromatid exchange and
chromosomal aberrations in Chinese hamster ovary (CHO) cells with
and without exogenous metabolic activation (58,59). No genotoxic
effect in E.coli K12 was observed in a host-mediated assay after
feeding of 2,6-DMA to mice, nor was feeding or injecting it effective
in a sex-linked recessive lethal assay in Drosophila melanogaster
(58). No increase of micronuclei was detected in the bone marrow
of male mice after oral doses of up to 375 mg/kg/day (60) and it did
not induce unscheduled DNA synthesis in rat hepatocytes (61).
N-hydroxy-2,6-DMA, the proposed product of metabolic activation
of 2,6-DMA in vivo, was mutagenic in S.typhimurium TA100 (62) and
Fig. 6. Formation of protein adducts by aminophenols. A fundamental question posed by this article is whether similar reactions occur between aminophenols
and DNA.
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O
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Fig. 7. Proposed metabolic pathways leading to formation of genotoxic DNA damage products of 2,6-DMA. Modified from Gan et al. (24).
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was the most mutagenic member of a series of N-hydroxylated aniline
derivatives in the absence of metabolic activation (30,63). N-hydroxy-
3,5-DMA was mutagenic in the HPRT gene of human lymphoblastoid
TK6 cells (see below; 64).
Because of the diversity of exposure conditions, target genomes
and host cells in which mutagenic events produced by carcinogenic
aromatic amines have been studied, extrapolation of observations
from one system to another entails substantial uncertainty. The spectra
of DNA lesions created also differ qualitatively and quantitatively,
and the modified bases identified in any given experiment probably
represent only a subset of lesions actually present. Thus, it is difficult
to formulate valid generalizations regarding mutagenic efficiency of
specific DNA lesions or mechanisms through which they are created.
In view of the widespread human exposure to alkylanilines and other
evidence summarized in the preceding sections, we have undertaken
investigations to expand the database concerning their genotoxicity in
mammalian cell systems. We are systematically investigating muta-
genic responses and mutation spectra induced by metabolites of al-
kylanilines that have received little previous study. Evaluations are
being done in well-defined genetic targets and mutagenesis models
exposed under controlled conditions with the ultimate objective of iden-
tifying DNA alterations responsible for specific mutational events. To
date, our studies of cytotoxicity have focused exclusively on cell sur-
vival, assessed by dye exclusion 24 h after exposure to test compounds.
We have focused on three members of this group, namely 3-EA,
2,6-DMA and 3,5-DMA, and their N-hydroxy and aminophenol me-
tabolites synthesized as described above. Initial studies conducted in
human lymphoblastoid TK6 cells revealed that 3-EA and N-hydoxy-
3-EA did not cause reduced viability and were not mutagenic to cells
exposed to millimolar concentrations and they have not been studied
further. In contrast, 2,6- and 3,5-DMA both induced cell death, but
exhibited considerable variation in potency, in which the aminophenol
metabolites were considerably more potent than the corresponding
N-hydroxylamines. Also, each metabolite of 3,5-DMAwas more toxic
than its 2,6-DMA counterpart. When these compounds were tested for
HPRT mutagenicity, both the N-hydroxy and aminophenol of 3,5-
DMA were clearly mutagenic but these derivatives of 2,6-DMA were
not active over the same range of dose levels (64).
We have also studied cytotoxicity and mutagenesis induced by the
alkylanilines and their major metabolites in AS52 cells, which were
derived from HPRT CHO cells, and contain a functional single copy
of the E.coli gpt gene in an SV40-pBR322 plasmid stably integrated
into their genomic DNA (65–68). The gpt gene encodes the purine
salvage pathway enzyme xanthine-guanine phophoribosyl transfer-
ase, analagous to mammalian HPRT, and thus provides the basis for
6-thioguanine selection of mutants. The system is highly suited for
determining mutational spectra induced by chemical mutagens of
different types. Results to date show that 2,6-DMA and 3,5-DMA
when activated by a human liver S9 preparation were both cytotoxic
and mutagenic, showing linear dose-response relationships in both
parameters at exposure levels between 10 lM and 1 mM. Their
N-hydroxy derivatives were also cytotoxic and mutagenic, but had
higher potency, showing comparable dose-related responses at expo-
sure levels between 10 and 100 lM. Similarly, their aminophenols
were both cytotoxic and mutagenic and were substantially more po-
tent, causing nearly 100% cell killing and significant mutagenicity at
levels below 10 lM. Mutation spectra induced by these treatments are
currently under investigation.
We are also characterizing alkylaniline genotoxicity in cell systems
designed to provide further information about their metabolic activa-
tion. Felton et al. (69,70) developed CHO-derived cell lines in which
both phase I and phase II enzymes were introduced and have shown
these cells to be highly sensitive to mutagenesis by the heterocyclic
amine 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. CHO
AA8 cells served as the original source of the UV5 line, which lacks
nucleotide excision repair (NER) due to an induced defect in the XPD
(ERCC2) gene (70,71). Transfection of UV5 cells with mouse P450
1A2 complementary DNA established the UV5P3 line (72), which
was subsequently transfected with human aryl sulfotransferase
(HAST1) or NAT2 from a human liver complementary DNA library
(70,73), producing CHO cells that are NER deficient (or proficient)
and express mouse P4501A2 plus human aryl sulfotransferase or NAT
genes. Based on their heterozygosity at the aprt locus, they can be
used for mutational analysis based on selection with 8-azaadenine.
Cells were treated with the parent alkylanilines 2,6-DMA and 3,5-
DMA at exposure levels of 50 lM–1 mM or with N-hydroxy or
aminophenol metabolites at 5–500 lM. Cell viability was determined
24 h after treatment by trypan blue exclusion and mutant fraction by
8-azaadenine selection. Major findings of studies to date can be sum-
marized as follows. The influence of NER status was investigated by
comparison of responses of AA8 CHO cells, which are NER profi-
cient, and UV5 cells, which are NER deficient. Neither cell line ex-
presses significant levels of phase I nor phase II enzymes. In the
absence of human liver S9, the parent alkylanilines were cytotoxic,
but not mutagenic, at exposure levels of 100 lM–1 mM, as expected.
Interestingly, cytotoxicity was enhanced by NER deficiency, sug-
gesting that DNA damage by products that were not mutagenic in
the assay used contributed to the toxicity of the compounds. The
N-hydroxy derivatives of 2,6-DMA and 3,5-DMA were also toxic,
causing dose-related loss of viability at doses between 100 lM and
1 mM; toxic potency was substantially increased by NER deficiency,
resulting in similar loss of viability at levels of 10–200 lM. These
derivatives were not mutagenic at doses up to 1 mM. Responses to the
aminophenol derivatives were virtually identical to those of the
N-hydroxylated forms, i.e. they were potent inducers of cytotoxicity,
which was enhanced by NER deficiency, but not mutagenic under
these conditions.
The influence of NER status was also studied by several other
comparisons. In two cell lines both expressing CYP1A2 and NAT2,
but one deficient in NER, 2,6-DMA and 3,5-DMA were cytotoxic and
mutagenic at dose levels between 100 lM and 1 mM. Their potency in
inducing both responses was greatly enhanced in the NER-deficient
cells. In two cell lines both deficient in NER and one expressing
CYP1A2 and NAT2, 2,6-DMA and 3,5-DMA were cytotoxic at dose
levels of 100 lM –1 mM but were mutagenic only in cells expressing
the metabolizing enzymes, as expected. Very similar results were
obtained in a comparison of cells expressing CYP1A2 and aryl sulfo-
transferase. The relative contributions of aryl sulfotransferase and
NAT2 to the induction of cytotoxicity and mutagenicity were com-
pared in NER-deficient cells expressing CYP1A2 and either of the
phase II enzymes. Aryl sulfotransferase proved to be more effective in
potentiating cytotoxicity but not mutagenicity of both 2,6-DMA and
3,5-DMA.
Thus, results to date indicate that the alkylanilines are potent gen-
otoxins when activated by exogenous or endogenous phase I and
phase II xenobiotic-metabolizing enzymes. The nature of specific
DNA damage products responsible for mutagenicity remains to be
identified, although evidence to date supports the suggestion that
activation through N-hydroxylation and subsequent conjugation by
sulfation and/or acetylation are important contributors. It is also ev-
ident that NER is an important determinant of the magnitude of mu-
tagenic responses. Interestingly, repair deficiency also enhances
cytotoxicity under conditions in which mutagenicity is not detected,
suggesting that DNA damage other than proposed DNA adducts may
also be important in determining the observed responses.
NER of DNA is essential for maintenance of genomic integrity and
cell viability. Different types of DNA lesions have distinct consequen-
ces with respect to helix distortion as well as ability to suspend or
obstruct DNA replication, block ongoing transcription or hamper the
battery of genome repair systems and caretakers that continuously
safeguard the genome (74). Depending on the type of DNA damage,
cell death may be triggered via apoptosis or replicative senescence
(cytotoxic or cytostatic lesions, e.g. double-strand breaks) or muta-
tions may be induced by DNA adducts of various structural types.
NER is primarily involved in repair of severely helix-distorting dam-
age, such as bulky nucleotide adducts and intrastrand crosslinks that
interfere with base pairing, thereby interfering with transcription and
normal replication. Current evidence suggests that different DNA
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adducts may induce very different effects on cell proliferation, cell
death via necrosis or apoptosis, as well as mutagenicity, possibly
attributable to activation of cellular responses such as p53 activation.
The importance of NER status and the nature of DNA adducts as
determinants of cytotoxicity and mutagenicity is well illustrated by
results of a comparison of cytotoxicity and mutagenicity of a series of
carcinogens in normal diploid human fibroblasts and in cells deficient
in one or more DNA repair processes (75). Carcinogens studied in-
cluded UV radiation; reactive derivatives of structurally related aro-
matic amides; metabolites of benzo[a]pyrene; the alkylating agent
MNNG and aflatoxin B1 dichloride, a model for the reactive 2,3-
epoxide of aflatoxin B1. Exponentially growing cells were exposed
to agents and assayed for mutations (induction of 6-thioguanine re-
sistance) and cell killing (loss of colony-forming ability). Cells de-
ficient in repair of particular DNA adducts or lesions proved more
sensitive to the agent causing those lesions than did normally repair-
ing cells. These results are similar to our observations on alkylani-
lines. Many of the carcinogens were compared for their mutagenic
and/or cytotoxic effect not only as a function of dose administered but
also as a function of the initial number of adducts or photoproducts
induced in DNA and the number remaining at critical times posttreat-
ment. The results demonstrated a high correlation between the num-
ber of DNA lesions remaining unexcised at the time the DNA was
replicated and the frequency of mutations induced. These observa-
tions will need to be taken into account in interpreting results of our
future studies, and extensive further investigations will be required for
more complete elucidation of underlying mechanisms.
Summary
Alkylanilines comprise a class of chemicals that, while clearly not as
carcinogenic as multi-ring aromatic amines, may hold far more signif-
icance for human health than has yet been appreciated. It appears that
few individuals are spared lifelong exposure to many of these com-
pounds. The universal nature of exposure results from an abundance of
sources, some, like tobacco smoke that are well documented and others
that are poorly understood but that may reflect the widespread use of
alkylanilines as components of numerous pharmaceuticals and chem-
ical commodities. Whether their potency is sufficient to create substan-
tial attributable risk remains an unresolved question but there is
certainly some evidence to that effect with regard to bladder cancer
and several specific amines. Research on the mechanisms of action of
alkylanilines has yet to produce a well-defined model like the model for
multi-ring aromatic amines. The present lack of a model may reflect
more than a lower level of interest; the mechanisms may actually be
more complex ranging from nitrenium ion chemistry to reactions in-
volving quinone imines and possibly encompassing the chemistry of
ROS. The potential mechanistic complexity of alkylanilines relative to
multi-ring aromatic amines is an especially important aspect of their
genotoxicity. The carcinogenic multi-ring aromatic amines are deemed
to target the urinary bladder in part because the ultimate electrophilic
form, a nitrenium ion, is transported in a stable form to the bladder,
where it becomes available through a change in acidity. If additional
mechanisms that do not require a bladder-specific environment are
characteristic of alkylanilines, then there is reason to expect that they
may target additional organs such as the kidney, for which there are few
candidate chemical carcinogens. A better understanding of the mech-
anisms of alkylaniline genotoxicity is probably to provide important
insights into the environmental and genetic origins of one or more
human cancers and may reveal a substantial role for this group of
compounds as human chemical carcinogens.
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